secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-07-22T23:59:59+00:00
Accession:  0001193125-22-200068
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme EVP of R&D Leslie Holsinger resigns effective July 31, 2022
---------------------------------------------------------------------

- Dr. Holsinger receives $339,000 cash severance (9 months' base salary) in a lump sum.
- Health care continuation benefits and 12-month extension of vested equity exercise period provided.
- Additional change-in-control severance and accelerated vesting available if a change in control occurs within 3 months post-departure.
- Company anticipates entering into a consulting agreement with Dr. Holsinger for transition through year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522200068/0001193125-22-200068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522200068/d383988d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-200068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer